Pharmacokinetics of oral terguride in patients with a prolactinoma.
The pharmacokinetics of oral terguride 1 mg was evaluated in a single-dose study in 8 patients with a prolactinoma and one with acromegaly. A radioreceptor assay was used to measure the plasma levels of terguride. The peak plasma concentration (2.3 +/- 0.7 ng/ml, mean +/- SEM) was attained within 1 h of drug administration. Moment analysis gave a mean residence time of 4.3 +/- 0.6 h. Plasma prolactin was also determined by radioimmunoassay. The plasma prolactin was reduced to 30 +/- 3% of its pretreatment value after 4 h.
D000172:Acromegaly / Q000378:metabolism; D000328:Adult; D004873:Ergolines / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008090:Lisuride / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D004873:Ergolines; C006208:dironyl; D011388:Prolactin; D008090:Lisuride